Effects of Ornithine Aspartate and Empagliflozin on Memory Deficit Symptoms in Experimental Steatohepatitis
https://doi.org/10.33647/2074-5982-18-3-128-132
Abstract
In this study, L-ornithine L-aspartate and empagliflozin were evaluated in terms of their potential effects on the hippocampus-dependent memory status in non-alcoholic steatohepatitis (NASH) in C57Bl/6 mice. NASH was found to be associated with an early transient decrease in the short-term recognition memory as well as a progressive reduction in the short-term spatial memory. L-ornithine L aspartate effectively prevented the impairment of recognition, rather than spatial, memory. At the same time, empagliflozin failed to improve the memory status of the animals.
About the Author
V. A. Prikhodko
St. Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Veronika A. Prikhodko.
197376, St. Petersburg, Professora Popova Str., 14, lit. A.
References
1. Broadbent N.J., Squire L.R., Clark R.E. Spatial memory, recognition memory, and the hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2004;101(40):14515-14520. DOI: 10.1073/pnas.0406344101.
2. Butterworth R.F. L-Ornithine L-Aspartate (LOLA) for the treatment of hepatic encephalopathy in cirrhosis: Novel insights and translation to the clinic. Drugs. 2019;79(Suppl 1):1-3. DOI: 10.1007/s40265-018-1021-4.
3. Deacon R.M., Rawlins J.N. T-maze alternation in the rodent. Nat. Protoc. 2006;1(1):7-12. DOI: 10.1038/nprot.2006.2.
4. George E.S., Sood S., Daly R.M., Tan S.Y. Is there an association between non-alcoholic fatty liver disease and cognitive function? A systematic review. BMC Geriatr. 2022;22(1):47. DOI: 10.1186/s12877-021-02721-w.
5. Higarza S.G., Arboleya S., Gueimonde M., Gomez-Lazaro E., Arias J.L., Arias N. Neurobehavioral dysfunction in non-alcoholic steatohepatitis is associated with hyperammonemia, gut dysbiosis, and metabolic and functional brain regional deficits. PLoS One. 2019;14(9):e0223019. DOI: 10.1371/journal.pone.0223019.
6. Kjærgaard K., Mikkelsen A.C.D., Wernberg C.W., Grønkjær L.L., Eriksen PL., Damholdt M.F., Mookerjee R.P., Vilstrup H., Lauridsen M.M., Thomsen K.L. Cognitive dysfunction in non-alcoholic fatty liver disease-current knowledge, mechanisms and perspectives. J. Clin. Med. 2021;10(4):673. DOI: 10.3390/jcm10040673.
7. Leger M., Quiedeville A., Bouet V., Haelewyn B., Boulouard M., Schumann-Bard P., Freret T. Object recognition test in mice. Nat. Protoc. 2013;8(12):2531-2537. DOI: 10.1038/nprot.2013.155.
8. Prikhodko V.A., Sysoev Yu.I., Poveryaeva M.A., Bunyat A.V., Ivkin D.Y., Sukhanov D.S., Shustov E.B., Okovityi S.V., Karev V.E. Effects of empagliflozin and L-ornithine L-aspartate on behavior, cognitive functions, and physical performance in mice with experimentally induced steatohepatitis. Bull. Russ. State Med. Univ. 2020;(3):49-57. DOI: 10.24075/brsmu.2020.034.
9. Tsuchida T., Lee Y.A., Fujiwara N., Ybanez M., Allen B., Martins S., Fiel M.I., Goossens N., Chou H.I., Hoshida Y., Friedman S.L. A simple diet-and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver. J. Hepatol. 2018;69(2):385-395. DOI: 10.1016/j.jhep.2018.03.011.
Review
For citations:
Prikhodko V.A. Effects of Ornithine Aspartate and Empagliflozin on Memory Deficit Symptoms in Experimental Steatohepatitis. Journal Biomed. 2022;18(3):128-132. (In Russ.) https://doi.org/10.33647/2074-5982-18-3-128-132
Views:
265
Email this article 
